RxDoctor Payments DataLook up a doctor →

Kenneth Lander, MD

Pulmonary Disease · Upland, PANPI 1154318988

Payments from drug & device makers

$646,768in general payments, 2019–2025

Across 1,723 payments — averaging $375.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$590K
  • Mallinckrodt Enterprises LLC$23K
  • Boehringer Ingelheim$8K
  • Mallinckrodt Hospital Products Inc.$6K
  • Bayer$3K
  • GSK$3K
  • plus $13K from 40 others

What the payments were for

  • Consulting fees$6,6271%
  • Speaking & faculty fees$547,22385%
  • Travel & lodging$53,8678%
  • Food & beverage$38,5316%
  • Education$5200%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$646,768 in reported general payments places this provider in the 95th percentile of 703 pulmonary disease providers in Pennsylvania.

See all pulmonary disease providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$439,013
Medicare patients
599
Services billed
4,900

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
AdempasRiociguat50$647,112
Trelegy ElliptaFluticasone/Umeclidin/Vilanter542$396,011
Breztri AerosphereBudesonide/Glycopyr/Formoterol335$223,713
LetairisAmbrisentan12$155,338
Pirfenidone13$93,182
Spiriva RespimatTiotropium Bromide68$50,674
Breo ElliptaFluticasone/Vilanterol114$49,856
Advair HfaFluticasone Propion/Salmeterol132$46,394
XareltoRivaroxaban33$25,971
Stiolto RespimatTiotropium Br/Olodaterol Hcl37$25,922
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate83$21,178
SymbicortBudesonide/Formoterol Fumarate71$20,720
Albuterol Sulfate HfaAlbuterol Sulfate669$19,643
EliquisApixaban24$15,929
Combivent RespimatIpratropium/Albuterol Sulfate15$14,575

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
BayerAdempas$3,162$647,11250 claims
GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta$2,784$454,390681 claims
AstraZenecaBreztri Aerosphere, Symbicort, Bevespi Aerosphere$590,397$252,082424 claims
Boehringer IngelheimSpiriva Respimat, Stiolto Respimat, Combivent Respimat$8,381$91,171120 claims
Johnson & JohnsonXarelto$974$25,97133 claims
PfizerEliquis$22$15,92924 claims
MerckDulera$33$7,08313 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 703 pulmonary disease providers in Pennsylvania.

Other pulmonary disease in Upland

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →